Companies · Biotechnology

Circula-AI Inc

BOCA RATON · Biotechnology

Diligence memoA one-page analyst read on Circula-AI Inc — recommendation, valuation, rhythm, risks.
$7.6M
Total raised · real
5
Rounds
0.5×
Latest step-up
Top 50%
Sector rank · raised
Seed
Latest stage · inferred · Wed Mar 18 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Circula-AI Inc looks under-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.47× the median modeled value of Seed Biotechnology companies in 2025–2027 (99 peers) — value vs value, same stage and era.
Active
  • Last raise 3 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Circula-AI Inc is one of 4293 Biotechnology companies tracked from BOCA RATON. By capital raised it ranks mid-pack (ahead of 51% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

ai/ml

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
7
Investors (latest)
2026-03-18
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$2.5M$5.0M$7.5M$10MSeed · 2025-01-06 Raised $2.2M (real) Modeled valuation $8.0M (est)$2.2M$8.0MSeed2025Seed · 2025-05-12 Raised $351K (real) Modeled valuation $1.1M (est)$351K$1.1MSeed2025Seed · 2025-08-19 Raised $1.7M (real) Modeled valuation $4.3M (est)$1.7M$4.3MSeed2025Seed · 2025-10-22 Raised $2.2M (real) Modeled valuation $5.3M (est)$2.2M$5.3MSeed2025Seed · 2026-03-18 Raised $1.2M (real) Modeled valuation $2.2M (est)$1.2M$2.2MSeed2026+$351K+$1.7M+$2.2M+$1.2MCumulative $7.6M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.2M · 2025
Seed extension$351K · 2025
Seed extension$1.7M · 2025
Seed extension$2.2M · 2025
Seed extension$1.2M · 2026

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$2.2M
Base estimate est.
$829K
Conservative case
$3.6M
Upside case
$5.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $8.0M · 2025-01-062025Seed · modeled $1.1M · 2025-05-12Seed · modeled $4.3M · 2025-08-19Seed · modeled $5.3M · 2025-10-22Seed · modeled $2.2M · 2026-03-182026
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
0.3 yr
Elapsed time used
0.3 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
4 mo
Avg between rounds
$6.4M/yr
Capital velocity
1.5 yr
On record since
2025
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.1× above median
This company$7.6M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.7× of median
This company$1.2M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$2.2M
Sector median$64.2M

Raised more than 51% of sector peers (real $). Modeled value above 5% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #77 of 99.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0M$10.0MCapital raised (log)Carna Inc. · Seed Raised $3.4M · modeled $12.4M (est)NRX Pharmaceuticals, Inc. · Seed Raised $3.5M · modeled $12.3M (est)Vicora, Inc. · Seed Raised $3.4M · modeled $11.9M (est)MH3D, Inc. · Seed Raised $3.3M · modeled $11.9M (est)Oral Genome Corp. · Seed Raised $3.1M · modeled $11.2M (est)Synlico Inc. · Seed Raised $5.2M · modeled $10.1M (est)Auxilium Biotechnologies Inc. · Seed Raised $7.2M · modeled $9.7M (est)Silexion Therapeutics Corp · Seed Raised $3.6M · modeled $9.6M (est)Bodark Investment Group LP · Seed Raised $3.3M · modeled $9.4M (est)Sower Solas I Sidecar III, LLC · Seed Raised $3.5M · modeled $9.3M (est)Sift Biosciences, Inc. · Seed Raised $3.8M · modeled $8.5M (est)SiVEC Biotechnologies, Inc. · Seed Raised $3.3M · modeled $8.4M (est)Circula-AI Inc (this company) Raised $7.6M · modeled $2.2M (est)Circula-AI Inc
CompanyStageRaised · realValue · estvs peer med.
Carna Inc.Seed$3.4M$12.4M2.72×
NRX Pharmaceuticals, Inc.Seed$3.5M$12.3M2.70×
Vicora, Inc.Seed$3.4M$11.9M2.61×
MH3D, Inc.Seed$3.3M$11.9M2.61×
Oral Genome Corp.Seed$3.1M$11.2M2.45×
Synlico Inc.Seed$5.2M$10.1M2.22×
Auxilium Biotechnologies Inc.Seed$7.2M$9.7M2.13×
Silexion Therapeutics CorpSeed$3.6M$9.6M2.10×
Bodark Investment Group LPSeed$3.3M$9.4M2.06×
Sower Solas I Sidecar III, LLCSeed$3.5M$9.3M2.05×
Sift Biosciences, Inc.Seed$3.8M$8.5M1.85×
SiVEC Biotechnologies, Inc.Seed$3.3M$8.4M1.85×
Circula-AI Inc this companySeed$7.6M$2.2M0.47×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.2M2025-01-06$11.0M$8.0M90%
Seed$351K2025-05-12$1.8M$1.1M90%
Seed$1.7M2025-08-19$8.4M$4.3M90%
Seed$2.2M2025-10-22$11.2M$5.3M90%
Seed$1.2M2026-03-18$5.8M$2.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.2M2025-01-06
    • First recorded raise — entered as Seed.
    • 11 investors on this round.
  2. Seed$351K2025-05-12
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round 6.3× smaller than the prior — bridge or down round.
    • 10 investors on this round.
  3. Seed$1.7M2025-08-19
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round 4.8× larger than the prior — scaling up.
    • 7 investors on this round.
  4. Seed$2.2M2025-10-22
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 1.3× larger than the prior — scaling up.
    • 9 investors on this round.
  5. Seed$1.2M2026-03-18
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 1.9× smaller than the prior — bridge or down round.
    • 7 investors on this round.
Intelligence
2026 ~Q3
Modeled next raise · ~4mo cadence
$1.2M
Modeled next size est.range $1.2M$1.8M
0.5×
Last step-up
$6.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Albert F Hummel1 other2025-01
Brock F Smith2025-05
Cassandra F Davies2025-05
Prue F Freestone2025-05
Registry & provenance

Circula-AI Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
2055042
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Algorithm Sciences, Inc.BiotechnologySeed$7.2M$1.9Msame sector · same stage
Vitro Biopharma, Inc.BiotechnologySeed$7.1M$294Ksame sector · same stage
Enrich Biosystems Inc.BiotechnologySeed$8.2M$3.3Msame sector · same stage
SciTech Development L.L.C.BiotechnologySeed$6.5M$1.0Msame sector · same stage
Epinex Diagnostics IncBiotechnologySeed$9.1M$4.4Msame sector · same stage
Aionx Antimicrobial Technologies, Inc.BiotechnologySeed$6.3M$1.5Msame sector · same stage
Gila Therapeutics, Inc.BiotechnologySeed$6.2M$2.7Msame sector · same stage
Bioxytran, IncBiotechnologySeed$6.0M$1.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
CIRC Biosciences, Inc.BiotechnologySeries B$54.7M87%
Circinus Medical Technology LLCBiotechnologySeries A$46.1M86%
Genleap Ai Inc.BiotechnologySeries C$1.5B85%
Vitazi.AI, Inc.BiotechnologySeed$1.1M83%
Circulate Health, Inc.BiotechnologySeries A$43.3M83%
NanoSpot.ai, Inc.BiotechnologyPre-Seed$5.2M83%
Bio-AI Health Inc.BiotechnologySeed$2.8M83%
BioCircuit Technologies, Inc.BiotechnologySeries A$111.5M82%
Frequently asked
How much funding has Circula-AI Inc raised?
Circula-AI Inc has raised approximately $7.6M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Circula-AI Inc's estimated valuation?
Provath's modeled valuation for Circula-AI Inc is approximately $2.2M (modeled range $829K–$3.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Circula-AI Inc at?
Circula-AI Inc's latest modeled financing stage is Seed. Its most recent recorded round closed around Wed Mar 18.
What does Circula-AI Inc do and where is it based?
Circula-AI Inc operates in the Biotechnology sector, based in BOCA RATON.
Explore related

See where Circula-AI Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Circula-AI Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.